NYSE · ABT
Abbott Laboratories
$104.57+$1.93 (+1.88%)
Abbott Laboratories’s quoted price sits in the lower half of its reported 52-week range, 20.8% below the high.
Loading market information…
XETRA · SHL.DE · EUR
Stock price, dividends, earnings
Quote as of Oct 29, 2026, 04:35 PM UTC. Cached market data; not a live quote.
One-year closing-price history · EUR. Historical prices are not a forecast.
Siemens Healthineers AG’s quoted price sits in the upper half of its reported 52-week range, 13.7% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Siemens Healthineers AG’s forward annual dividend is €1.00 per share, paid annual. The forward yield is 2.33% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Siemens Healthineers AG’s next earnings report is currently expected on Nov 5, 2026, with estimated earnings per share of €0.68. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Siemens Healthineers AG’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Siemens Healthineers AG, a subsidiary of Siemens Aktiengesellschaft with its headquarters in Erlangen, Germany, is a global leader in medical technology. The company develops, produces, and distributes a comprehensive portfolio of diagnostic and therapeutic products and services, catering to healthcare providers worldwide. Its operations are organized into four distinct business segments. The Imaging segment delivers advanced medical imaging systems, encompassing magnetic resonance imaging (MRI), computed tomography (CT), X-ray technology, molecular imaging, and ultrasound solutions. The Diagnostics segment focuses on providing in-vitro diagnostic products and services for laboratory, molecular, and point-of-care applications, alongside workflow optimization tools and informatics solutions for healthcare facilities. Varian, another key segment, specializes in cancer care, offering cutting-edge technologies, services, and integrated solutions to hospital oncology departments. This includes enhancing workflow efficiency, providing clinical services and consulting, and deploying digital platforms for treatment and therapy management. Lastly, the Advanced Therapies segment supplies sophisticated products designed to facilitate image-guided minimally invasive treatments across various medical fields, such as cardiology, interventional radiology, and surgery. Its offerings include angiography systems, mobile C-arms, and a robotic-assisted platform specifically for endovascular coronary and peripheral vascular procedures. Beyond these core offerings, Siemens Healthineers also provides a suite of essential support services, such as equipment performance management, clinical education and e-learning programs, asset management, managed departmental services for laboratories and healthcare facilities, and expert consulting and digital health services.
Latest available per-share figures in EUR. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 01:54 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| Q2 2025 | May 7, 2025 | €0.61-1.14% vs estimate | €5.91B-6.15% vs estimate |
|---|
| Q1 2025 | Feb 6, 2025 | €0.51+6.46% vs estimate | €5.48B+2.04% vs estimate |
|---|
| Q4 2024 | Nov 6, 2024 | €0.67+4.69% vs estimate | €6.33B-3.52% vs estimate |
|---|
THE ANALYST VIEW
2 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$104.57+$1.93 (+1.88%)
Abbott Laboratories’s quoted price sits in the lower half of its reported 52-week range, 20.8% below the high.
$97.11+$2.33 (+2.46%)
Medtronic Plc’s quoted price sits in the upper half of its reported 52-week range, 8.67% below the high.
$311.36+$7.36 (+2.42%)
Stryker Corporation’s quoted price sits in the lower half of its reported 52-week range, 20.03% below the high.
$42.69+$0.26 (+0.61%)
Boston Scientific Corporation’s quoted price sits in the lower half of its reported 52-week range, 59.59% below the high.
$76.42+$0.60 (+0.79%)
GE HealthCare Technologies Inc.’s quoted price sits in the upper half of its reported 52-week range, 14.87% below the high.
CN¥178.42-CN¥0.58 (-0.32%)
Shenzhen Mindray Bio-Medical Electronics Co., Ltd.’s quoted price sits in the upper half of its reported 52-week range, 20.53% below the high.
€24.28+€0.04 (+0.17%)
Koninklijke Philips N.V.’s quoted price sits in the lower half of its reported 52-week range, 12.35% below the high.
¥2,409+¥40 (+1.69%)
Terumo Corporation’s quoted price sits in the upper half of its reported 52-week range, 10.41% below the high.
